Melatonin (N-acetyl-5-methoxytryptamine) is a chronobiotic hormone primarily synthesized and secreted by the pineal gland in response to darkness. It serves as the principal endogenous signal for the mammalian circadian system, orchestrating sleep-wake cycles, seasonal physiology, and various metabolic processes[1].
Biochemistry & Synthesis
Melatonin biosynthesis occurs through a multi-step enzymatic pathway originating from the essential amino acid tryptophan. The process involves:
- Tryptophan hydroxylase converts tryptophan to 5-hydroxytryptophan (5-HTP)
- Aromatic L-amino acid decarboxylase synthesizes serotonin (5-HT) from 5-HTP
- Arotyl-CoA N-acetyltransferase (AANAT) catalyzes the rate-limiting step, converting serotonin to N-acetylserotonin
- Hydroxyindole O-methyltransferase (HIOMT) methylates N-acetylserotonin to produce melatonin
Key Insight: AANAT activity exhibits the highest known circadian rhythm amplitude in mammals, increasing up to 500-fold at night compared to daytime levels[2].
The Circadian Rhythm Connection
The suprachiasmatic nucleus (SCN) of the hypothalamus acts as the master circadian pacemaker. Via a multisynaptic pathway through the superior cervical ganglion, the SCN modulates pineal melatonin secretion in direct response to ambient light detected by retinal ganglion cells containing melanopsin[3].
During daylight, noradrenergic signaling to the pineal gland is inhibited, suppressing melatonin production. As darkness falls, noradrenaline release increases, activating adenylate cyclase, elevating cAMP, and phosphorylating AANAT to initiate melatonin synthesis. This creates the characteristic nocturnal surge that signals "biological night" to peripheral tissues.
Receptors & Signaling Pathways
Melatonin exerts its effects primarily through two high-affinity G-protein coupled receptors:
- MT1 (Mel1A): Predominantly involved in sleep initiation, circadian phase resetting, and inhibition of retinal dopamine release. Activates Gi/Go proteins, reducing cAMP and hyperpolarizing neurons.
- MT2 (Mel1B): Critical for circadian pacemaker entrainment, regulation of sleep architecture, and modulation of photic phase shifts. Also Gi-coupled with distinct downstream signaling kinetics.
At higher pharmacological concentrations, melatonin can also bind to MT3 (5-HT1A receptor) and nuclear retinoid orphan receptors (RORΞ±/Ξ³), though physiological relevance remains debated[4].
Clinical Applications & Supplementation
Exogenous melatonin is widely used for circadian rhythm sleep-wake disorders, jet lag, and delayed sleep phase syndrome (DSPS). Clinical guidelines generally recommend:
- Dosing: 0.3β1 mg taken 1β2 hours before desired bedtime for phase advancement; 2β5 mg for jet lag depending on direction of travel
- Formulation: Immediate-release for sleep onset issues; controlled-release formulations for maintenance of sleep architecture
- Timing: Critical for therapeutic efficacy; morning administration can paradoxically delay sleep onset
Long-term safety profiles indicate minimal tolerance, dependence, or hangover effects at physiological doses. However, supraphysiological commercial doses (3β10 mg) may cause daytime grogginess, vivid dreams, or transient hormonal interactions[5].
Research Frontiers
Current investigations explore melatonin's antioxidant capacity, neuroprotective properties, and potential roles in oncology chronotherapy. Emerging analogs like ramelteon and tasimelteon offer receptor selectivity (MT1/MT2 agonism) with improved pharmacokinetic profiles for clinical deployment. Additionally, research into melatonin's modulation of immune function and metabolic homeostasis continues to expand its therapeutic horizon[6].